Kendle Launches New Global Biostatistics InfrastructurePR Newswire (press release)Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical ...and more »

PPD opens Ireland research facilityBizjournals.comThe Wilmington-based clinical research organization (Nasdaq: PPDI) has hired 21 people there so far and plans to expand the work force at the site to 250. ...and more »

Amarin Receives Special Protocol Assessment Agreement from the FDA ...WELT ONLINE, GermanyAmarin Corporation plc (NASDAQ:AMRN) today announced that it has reached agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for its planned Phase 3 registration clinical trial of AMR101 (ethyl-EPA) in ...

BUYINS.NET: Market Maker Surveillance Report. Top 6 Losing Stocks ...Trading Markets (press release), CAKendle International Inc. (NASDAQ: KNDL), a clinical research organization, provides clinical development services on a contract basis to the biopharmaceutical industry worldwide. The company's clinical development services include clinical trial ...

OTC Select Announces NASDAQ Mid-Day Daily Stock WatchTMCnet - 3 hours agoOTC Select also features companies on its website with research reports, analysis, and newsletters. OTC Select is an independent electronic publication that ...

Kendle to open office in IndiaBizjournals.com, NC - Jan 14, 2009Kendle (NASDAQ: KNDL), a contract research organization, also is targeting additional expansion in India in 2009, according to a news release. ...

Patient Recruitment Begins in India for Phase 3 Diabetes TrialPharmaceutical Processing, NJ - 8 hours agoSpherix Incorporated (NASDAQ:SPEX) reported that patient recruitment for its Phase 3 clinical trial of its potential type 2 diabetes drug, Naturlose(R), ...

Human Genome Sciences Reports Initial Results Of Randomized Phase ...Medical News Today (press release), UK - 7 hours agoHuman Genome Sciences, Inc. (Nasdaq: HGSI) reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL receptor antibody ...

Human Genome Sciences Reports Initial Results of Randomized Phase ...Biloxi Sun Herald,  USA - 9 hours ago2 -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today reported initial topline results from an ongoing randomized Phase 2 clinical trial of its TRAIL ...

Oculus Innovative Sciences Announces Additional Phase II Data for ...Ad-Hoc-News (Pressemitteilung), Germany - 3 minutes agoOculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced additional positive results from its US Phase II clinical trial evaluating Microcyn® ...